Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA – Get Ratings) have been assigned an average recommendation of ‘withhold’ from 10 analysts covering the company, MarketBeat Ratings reports. Three equity research analysts rated the company’s shares as sells, three as holds, and four as buys. The average 12-month price target for analysts who published a report on stocks last year is $10.88.
TEVA has been the topic of several research reports. Barclays raised its price target for Teva Pharmaceutical Industries from his $13.00 to $14.00 in a research report on Thursday, Feb. 9, giving the company an “Overweight” rating. Jefferies Financial Group downgraded Teva Pharmaceutical Industries from a ‘buy’ rating to a ‘pending’ rating and raised the company’s price target from $10.00 to $12.00 in a research report on Thursday, January 19. JPMorgan Chase & Company downgraded Teva Pharmaceutical Industries from a ‘neutral’ rating to an ‘underweight’ rating, setting the company’s target price at $10.00 from $11.00, in a research report on Monday, Nov. 14. reduced to dollars. Finally, Piper Sandler lowered his price target for Teva Pharmaceutical Industries from $8.00 to $7.00 in his Wednesday, Nov. 23 research report, giving the stock an “underweight” rating.
In another news from Teva Pharmaceutical Industries, EVP Sven Dethlefs sold 19,355 shares in the company in a transaction on Monday, March 6th. Stocks sold for an average of $9.93, with a total transaction value of $192,195.15 for him. Following the closing of the sale, the Executive Vice President now directly owns his 223,447 shares of the company, valued at $2,218,828.71. The transaction was disclosed in filings with the Securities and Exchange Commission, which can be accessed on the SEC’s website. In separate news, VP David Matthew Stark sold his 16,491 shares of stock on Monday, March 6th. The shares sold for an average of $9.93 for a total of $163,755.63. Following the closing of the transaction, the Vice President now owns directly his 52,449 shares in the company, valued at approximately $520,818.57. The sale was disclosed in filings with the Securities and Exchange Commission, which can be accessed via this hyperlink. Also, EVP Sven Dethlefs sold his 19,355 shares in a deal on Monday, March 6th. The shares sold for an average of $9.93 for a total of $192,195.15. Following the closing of the transaction, the Executive Vice President now owns 223,447 shares of the Company’s stock valued at $2,218,828.71. Please see here for the disclosure of this sale. Insiders say that in the past three months he has sold 158,884 shares of company stock worth $1,572,797. The insider owns his 0.82% of the company’s shares.
institution inflow and outflow
Recently, many large investors changed their holdings in TEVA. Bank of New York Mellon Corp raised its stake in Teva Pharmaceutical Industries by 1.6% in the first quarter. Bank of New York Mellon Corporation now owns 1,875,394 shares worth $17.609 million after acquiring an additional 28,920 of his shares during the previous quarter. PNC Financial Services Group Inc. increased his position at Teva Pharmaceutical Industries by 12.3% in the first quarter. PNC Financial Services Group Inc. now owns 119,076 shares of the company worth $1,118,000 after he purchased an additional 13,069 shares during the previous quarter. MetLife Investment Management LLC boosted his position in Teva Pharmaceutical Industries by 4.7% in the first quarter. MetLife Investment Management LLC now owns 95,953 shares of the company worth $901,000 after purchasing an additional 4,300 of his shares last quarter. BlackRock Inc. increased his position at Teva Pharmaceutical Industries by 3.7% in the first quarter. BlackRock Inc. now owns 41,648,716 shares worth $391,081,000 after purchasing an additional 1,494,814 shares during the previous quarter. Finally, Great West Life Assurance Co. Can increased his Teva Pharmaceutical Industries holding by 4.0% in the first quarter. After acquiring an additional 16,134 shares during this period, Great West Life Assurance Co. now has 420,533 shares of the company stock valued at $4,137,000. Currently 50.39% of the shares are owned by institutional investors.
Teva Pharmaceutical Price/Performance Ratio
NYSE TEVA shares opened at $9.32 on Friday. His 50-day moving average price for this business is $10.26 and his 200-day moving average price is $9.28. The company has a market capitalization of $10.35 billion, a PE ratio of -4.40, a price/earnings ratio of 2.86, and a beta of 1.22. The company has a quick ratio of 0.72, a current ratio of 1.05 and a debt to equity ratio of 2.20. Teva Pharmaceutical Industries has a 12-month low of $6.78 and a 12-month high of $11.44.
Teva Pharmaceutical Industries (NYSE: TEVA – Get Rating) last reported quarterly results on Wednesday, February 8. The company reported earnings of $0.68 per share for him in the quarter, beating analyst consensus expectations of $0.64 by $0.04. The company’s revenue for the quarter was $3.88 billion, compared to consensus expectations of $3.9 billion. Teva Pharmaceutical Industries had a return on equity of 28.06% and a net profit margin of 15.76%. On average, analysts expect Teva Pharmaceutical Industries to post 2.31 EPS this year.
Teva Pharmaceutical Industries Company Profile
Teva Pharmaceutical Industries Ltd. develops, manufactures and markets pharmaceutical products. It operates through geographic segments of North America, Europe, and international markets. The company was founded in his 1901 and is headquartered in Tel Aviv, Israel.
This instant news alert was generated by Narrative Science Technology and MarketBeat financial data to provide our readers with the fastest and most accurate reporting. This article was reviewed by MarketBeat’s editorial team prior to publication. Send any questions or comments about this story to email@example.com.
Before you consider Teva Pharmaceutical Industries, listen to this.
MarketBeat tracks Wall Street’s most acclaimed and top performing research analysts and the stocks they recommend to clients every day. MarketBeat has identified five stocks top analysts are quietly whispering to their clients to buy now before the broader market catches on…and Teva Pharmaceutical Industries is on the list. It was not in
Teva Pharmaceutical Industries is currently rated as a “hold” among analysts, but top-rated analysts believe these five stocks are better buys.
See 5 stocks here